Skip to main content
    C

    CorMedix Inc (CRMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.82
    +0.16 (+3.43%)

    Market Cap: $370.64M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    CorMedix Inc (CRMD) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    CorMedix (CRMD) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, CorMedix reported EPS of -$0.04, above the -$0.09 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    63%(25/40)
    Avg Surprise
    +10.39%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.17
    Range-$0.25 - -$0.13
    7 analysts
    Revenue Consensus
    $54.47M
    Range$50.96M - $57.49M
    7 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.01
    Range-$0.01 - -$0.01
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago-$0.02+50.0%
    7d ago-$0.02+50.0%
    Current-$0.01
    Revenue Consensus
    $66.91M
    Range$66.91M - $66.91M
    1 analysts

    Next Report

    CRMD has an expected report date of Mar 3, 2027.

    CRMD Earnings Call

    The latest CRMD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CRMD beat 25, missed 13 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $54.52M, down 47.7% from $104.28M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.04-$0.09-$0.20 - -$0.05+55.56%Beat-102.8%61 up, 2 downNov 12, 2026$54.52M
    Jun 30, 2026$0.29$0.26$0.15 - $0.33+11.54%Beat+3.6%51 up, 0 downAug 13, 2026$101.93M
    Mar 31, 2026$0.35$0.33$0.33 - $0.33+6.06%Beat+16.7%20 up, 0 downMay 14, 2026$127.43M
    Dec 31, 2025$0.16$0.74$0.67 - $0.97-78.24%Miss-27.2%30 up, 1 downMar 5, 2026$118.37M
    Sep 30, 2025$1.41$0.63$0.30 - $1.02+123.81%BeatN/A72 up, 0 downNov 12, 2025$104.28M
    Jun 30, 2025$0.28$0.20$0.06 - $0.25+40.00%BeatN/A74 up, 0 downAug 7, 2025$39.74M
    Mar 31, 2025$0.30$0.25$0.17 - $0.30+20.00%BeatN/A64 up, 0 downMay 6, 2025$39.08M
    Dec 31, 2024$0.22$0.14$0.05 - $0.21+57.14%BeatN/A53 up, 0 downMar 25, 2025$31.21M
    Sep 30, 2024-$0.05-$0.10-$0.13 - -$0.06+50.00%BeatN/A40 up, 0 downOct 30, 2024$11.46M
    Jun 30, 2024-$0.25-$0.25-$0.27 - -$0.230.00%In lineN/A40 up, 0 downAug 14, 2024$806119
    Mar 31, 2024-$0.25-$0.28-$0.32 - -$0.25+10.71%BeatN/A40 up, 0 downMay 9, 2024N/A
    Dec 31, 2023-$0.26-$0.20-$0.21 - -$0.18-30.00%MissN/A40 up, 0 downMar 12, 2024$304110
    Sep 30, 2023-$0.17-$0.21-$0.23 - -$0.19+19.05%BeatN/A40 up, 0 downNov 14, 2023N/A
    Jun 30, 2023-$0.25-$0.24-$0.26 - -$0.22-4.17%MissN/A30 up, 0 downAug 8, 2023N/A
    Mar 31, 2023-$0.24-$0.20-$0.20 - -$0.20-20.00%MissN/A30 up, 0 downMay 15, 2023N/A
    Dec 31, 2022-$0.20-$0.19-$0.20 - -$0.17-5.26%MissN/A30 up, 0 downMar 30, 2023$29702
    Sep 30, 2022-$0.17-$0.23-$0.25 - -$0.20+26.09%BeatN/A30 up, 0 downNov 10, 2022$6817
    Jun 30, 2022-$0.19-$0.21-$0.21 - -$0.20+9.52%BeatN/A30 up, 0 downAug 11, 2022$21253
    Mar 31, 2022-$0.18-$0.22N/A+18.18%BeatN/A33 up, 0 downMay 12, 2022$7636
    Dec 31, 2021-$0.20-$0.23-$0.27 - -$0.21+13.04%BeatN/A30 up, 0 downMar 29, 2022$56396
    Sep 30, 2021-$0.22-$0.18-$0.18 - -$0.17-22.22%MissN/A32 up, 0 downNov 9, 2021$38088
    Jun 30, 2021-$0.12-$0.19-$0.22 - -$0.13+36.84%BeatN/A4N/AAug 12, 2021$8191
    Mar 31, 2021-$0.20-$0.18-$0.20 - -$0.16-11.11%MissN/A5N/AMay 13, 2021$88261
    Dec 31, 2020-$0.19-$0.22-$0.25 - -$0.21+13.64%BeatN/A5N/AMar 30, 2021$55713
    Sep 30, 2020-$0.22-$0.25-$0.30 - -$0.22+12.00%BeatN/A4N/ANov 5, 2020$93020
    Jun 30, 2020-$0.14-$0.24-$0.24 - -$0.04+41.67%BeatN/A2N/AAug 10, 2020$16443
    Mar 31, 2020-$0.21-$0.23-$0.23 - -$0.23+8.70%BeatN/A2N/AMay 11, 2020$74054
    Dec 31, 2019-$0.21-$0.24-$0.25 - -$0.23+12.50%Beat-310.0%2N/AMar 16, 2020$24778
    Sep 30, 2019-$0.22-$0.25-$0.25 - -$0.25+12.00%BeatN/A2N/ANov 14, 2019$59530
    Jun 30, 2019-$0.24-$0.21-$0.22 - -$0.21-14.29%MissN/A2N/AAug 13, 2019$35266
    Mar 31, 2019-$0.22-$0.28-$0.29 - -$0.28+21.43%BeatN/A2N/AMay 13, 2019$163692
    Dec 31, 2018$0.10-$0.40-$0.50 - -$0.30+125.00%BeatN/A2N/AMar 14, 2019$26522
    Sep 30, 2018-$0.55-$0.30N/A-83.33%MissN/AN/AN/ANov 14, 2018$372514
    Jun 30, 2018-$0.50-$0.50-$0.50 - -$0.500.00%In lineN/A1N/AAug 14, 2018$7551
    Mar 31, 2018-$0.70-$0.50-$0.50 - -$0.50-40.00%MissN/A1N/AMay 15, 2018$23210
    Dec 31, 2017-$0.77-$0.60-$0.60 - -$0.60-28.33%MissN/A1N/AMar 19, 2018$92525
    Sep 30, 2017-$0.66-$0.65N/A-1.54%MissN/AN/AN/ANov 9, 2017$61075
    Jun 30, 2017-$0.67-$0.80N/A+16.25%BeatN/AN/AN/AAug 9, 2017$136168
    Mar 31, 2017-$0.95-$0.72N/A-31.94%MissN/AN/AN/AMay 10, 2017$39559
    Dec 31, 2016-$0.80-$1.07N/A+25.23%BeatN/AN/AN/AMar 16, 2017$121716
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.15, a profit after a loss of $0.33 per share the year before. It was -$3.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.15N/A
    Dec 31, 2024-$0.33N/A
    Dec 31, 2023-$0.92N/A
    Dec 31, 2022-$0.74N/A
    Dec 31, 2021-$0.74N/A
    Dec 31, 2020-$0.76N/A
    Dec 31, 2019-$0.89N/A
    Dec 31, 2018-$1.65N/A
    Dec 31, 2017-$3.05N/A
    Dec 31, 2016-$3.20N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,300 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,28210
    2026Q2Jun 30, 20263,75310
    2026Q1Mar 31, 20264,86012
    2025Q4Dec 31, 20254,1559
    2025Q3Sep 30, 20255,16210
    2025Q2Jun 30, 20253,62310
    2025Q1Mar 31, 20254,1029
    2024Q4Dec 31, 20244,83811

    2026Q3 Earnings Call

    Opening remarks

    Daniel Ferry Representative, Life Science Advisors Good morning, and welcome to the CorMedix Third Quarter 2026 Earnings and Corporate Update Conference Call. Leading the call today is Joe Todisco, Chairman and Chief Executive Officer of CorMedix. He is joined by Susan Blum, EVP and Chief Financial Officer. In addition, Liz Hurlburt, EVP and Chief Commercial Officer, and Beth Zelnick Kaufman, EVP and Chief Legal and Compliance Officer and Corporate Secretary, will be available during the Q&A session. Before we begin, I would like to remind everyone that during the call, we may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management's expectations, beliefs, goals, and plans about the company's prospects and future financial position. Actual results may differ materially from the estimates on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in CorMedix's filings with the SEC, which are available free of charge on the SEC's website or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in these forward-looking statements, and investors should not place undue reliance on these statements. CorMedix does not intend to update these forward-looking statements except as required by law. On this call, the company will discuss certain non-GAAP measures of its performance. GAAP-to-non-GAAP financial reconciliations and supplemental financial information are provided in CorMedix's earnings release and the current report on Form 8-K filed with the SEC. This information is also available on the Investor Relations section of CorMedix's website. In addition, today's discussion includes statements regarding CorMedix's proposed acquisition of substantially all the assets of Heron Therapeutics, which remains subject to approval by Heron's stockholders, regulatory clearance, and other customary closing conditions. CorMedix has filed a current report on Form 8-K describing the proposed transaction in greater detail. Investors are urged to read it and any other relevant documents CorMedix has filed with the SEC carefully and in their entirety because they contain important information about the proposed transaction. At this time, it is now my pleasure to turn the call over to Joe Todisco, Chairman and Chief Executive Officer of CorMedix. Joe, please go ahead.

    Joseph Todisco Chairman and CEO Thanks, Daniel. Good morning, everyone, and thank you for joining us on this call. On Monday, we announced the definitive agreement to acquire substantially all of the assets of Heron Therapeutics, encompassing both commercial and pipeline assets that we believe are highly complementary and synergistic with CorMedix's growth strategy in institutional settings of care. As we discussed on Monday, we see four pillars to the strategic rationale for this transaction.

    Frequently Asked Questions About CRMD

    When is CorMedix's next earnings date?

    CorMedix's next earnings report is expected for Mar 3, 2027.

    Did CRMD beat earnings estimates last quarter?

    Yes. CorMedix reported EPS of -$0.04 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 55.56% surprise.

    What EPS do analysts expect from CRMD next quarter?

    The consensus EPS estimate for CorMedix for the quarter ending Dec 31, 2026 is -$0.17 from 7 analysts, with estimates from -$0.25 to -$0.13.

    How often does CRMD beat earnings estimates?

    CorMedix beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +29.48%.